Deciphera Pharmaceuticals (DCPH) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free DCPH Stock Alerts $25.51 0.00 (0.00%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 4:44 AM | marketbeat.comBNP Paribas Financial Markets Boosts Stock Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)BNP Paribas Financial Markets boosted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 118.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,653 shares of thMay 26 at 7:13 AM | marketbeat.comTrexquant Investment LP Takes $2.19 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Trexquant Investment LP acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,994 shares of the company's stock,May 24, 2024 | americanbankingnews.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Consensus Recommendation of "Hold" by BrokeragesMay 24, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Recommendation of "Hold" from BrokeragesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and three have gMay 22, 2024 | msn.comDeciphera Pharmaceuticals ticks higher as HSR waiting period for ONO sale expiresMay 22, 2024 | marketbeat.comJump Financial LLC Takes $522,000 Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Jump Financial LLC purchased a new position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,375 shares of the company's stoMay 19, 2024 | marketbeat.comPanagora Asset Management Inc. Acquires 144,097 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Panagora Asset Management Inc. grew its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 157.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 235,845 shares of the company'sMay 16, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)May 14, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock SalesMay 13, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Strong Trading VolumeDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading VolumeMay 10, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 52-Week High at $25.55Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $25.55May 10, 2024 | investorplace.comDCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 10, 2024 | marketbeat.comFisher Asset Management LLC Acquires New Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Fisher Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 62,372 shares of the company's stock, vMay 2, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNKMay 1, 2024 | businesswire.comDECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPHMay 1, 2024 | msn.comBarclays Upgrades Deciphera Pharmaceuticals (DCPH)May 1, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Cut to Market Perform at Leerink PartnrsLeerink Partnrs cut Deciphera Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday.April 30, 2024 | msn.comJefferies Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Down 5.1% in AprilDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 5,750,000 shares, a drop of 5.1% from the March 31st total of 6,060,000 shares. Approximately 11.5% of the company's shares are sold short. Based on an average daily trading volume, of 525,500 shares, the days-to-cover ratio is presently 10.9 days.April 30, 2024 | markets.businessinsider.comDeep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)April 30, 2024 | msn.comJonesTrading Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Large Volume IncreaseDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading VolumeApril 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Earns "Neutral" Rating from GuggenheimGuggenheim reiterated a "neutral" rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday.April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Rating Increased to Equal Weight at BarclaysBarclays raised shares of Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $9.00 to $26.00 in a research report on Tuesday.April 30, 2024 | finance.yahoo.comONO Enters into a Definitive Agreement to Acquire Deciphera PharmaceuticalsApril 30, 2024 | reuters.comJapan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansionApril 29, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPHApril 29, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a bApril 29, 2024 | msn.comDeciphera to be acquired by Japanese drug firm for $2.4 billionApril 29, 2024 | finance.yahoo.comUpdate: Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion DealApril 29, 2024 | finance.yahoo.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72%April 29, 2024 | marketbeat.comJefferies Financial Group Reaffirms Hold Rating for Deciphera Pharmaceuticals (NASDAQ:DCPH)Jefferies Financial Group restated a "hold" rating and issued a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday.April 29, 2024 | investorplace.comWhy Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?April 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.April 29, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 52-Week High at $25.03Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $25.03April 29, 2024 | barrons.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%April 29, 2024 | businesswire.comDCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to ShareholdersApril 29, 2024 | reuters.comJapan's ONO Pharmaceutical to buy Deciphera for $2.4 billionApril 29, 2024 | businesswire.comDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionApril 29, 2024 | marketbeat.comTrading was temporarily halted for "DCPH" at 06:04 AM with a stated reason of "News pending."April 27, 2024 | nasdaq.comDCPH Makes Notable Cross Below Critical Moving AverageApril 27, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Has $345,000 Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Allspring Global Investments Holdings LLC trimmed its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 70.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,382 shares of the company's stockApril 26, 2024 | seekingalpha.comDiving Into Deciphera PharmaceuticalsApril 17, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Sees Significant Increase in Short InterestDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 6,060,000 shares, a growth of 7.3% from the March 15th total of 5,650,000 shares. Approximately 12.3% of the company's stock are short sold. Based on an average daily volume of 540,200 shares, the days-to-cover ratio is currently 11.2 days.April 9, 2024 | businesswire.comDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 8, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Stock Price Down 3.6%Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Down 3.6%April 3, 2024 | marketbeat.comSG Americas Securities LLC Lowers Stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)SG Americas Securities LLC lowered its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 73.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 43,724 shares of the company's stock after selling 121,292 shares during the perMarch 25, 2024 | msn.comNovo Nordisk strikes deal worth up to $1.1 billion to expand cardio businessMarch 24, 2024 | finance.yahoo.comCompanies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In GrowthMarch 21, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Given New $16.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. upped their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Wednesday. Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. DCPH Media Mentions By Week DCPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DCPH News Sentiment▼1.240.92▲Average Medical News Sentiment DCPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DCPH Articles This Week▼82▲DCPH Articles Average Week Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GERN News Today VERA News Today RYTM News Today AMRX News Today INDV News Today AMPH News Today ARVN News Today RCKT News Today BHC News Today ZLAB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DCPH) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
